Charles Schwab Investment Management Inc Aldeyra Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 157,538 shares of ALDX stock, worth $866,459. This represents 0.0% of its overall portfolio holdings.
Number of Shares
157,538
Previous 137,985
14.17%
Holding current value
$866,459
Previous $793,000
23.96%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALDX
# of Institutions
132Shares Held
34.9MCall Options Held
244KPut Options Held
51.6K-
Knoll Capital Management, LLC Miami, FL5.48MShares$30.1 Million14.27% of portfolio
-
Perceptive Advisors LLC New York, NY4.05MShares$22.3 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$19.3 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT2.05MShares$11.3 Million1.29% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $321M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...